Transparency Life Sciences announced the successful completion of its VISITOR clinical trial. VISITOR was designed to assess the feasibility and ease, along with the quality and integrity, of collecting research-grade clinical data directly from subjects in their homes or offices using the Transparency Virtual Trials digital study hub.The study demonstrated that participants were able to adapt to using telemedicine devices to capture data commonly collected in clinical trials.
Read more about the study here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.